Company
cystetic Medicines
Molecular Prosthetics for Cystic Fibrosis
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Molecular prosthetics serve as functional replacements for the missing CFTR protein, thereby restoring critical airway function.
About the company
- Status notes
- cystetic Medicines has launched its first clinical candidate, CM001, in phase 1 clinical studies.
Products
- Other
- CM001
Loading relationship preview